Safety and efficacy of tegaserod therapy in patients with irritable bowel syndrome or chronic constipation

Journal of Population Therapeutics and Clinical Pharmacology

Volumn 17, Issue 1, 2010, Pages

  Al Judaibi, B ^a   Chande, N ^a   Gregor, J C ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Chronic constipation; Irritable bowel syndrome; Tegaserod

Indexed keywords

INDOLE DERIVATIVE; SEROTONIN 4 RECEPTOR; TEGASEROD;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; CHRONIC DISEASE; COMPARATIVE STUDY; CONSTIPATION; DIARRHEA; FEMALE; FOLLOW UP; HUMAN; IRRITABLE COLON; MALE; MIDDLE AGED; PHYSIOLOGY; RISK FACTOR; SAFETY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; CONSTIPATION; DIARRHEA; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDOLES; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; RECEPTORS, SEROTONIN, 5-HT4; RISK FACTORS; SAFETY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77958452881     PISSN: 17106222     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Talley NJ, Zinsmeister AR, Van Dyke C, Melton LJ, 3rd. Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology 1991 Oct;101(4):927-934.
2. Drossman DA, Li Z, Andruzzi E, et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci 1993 Sep;38(9):1569-1580.
3. Brandt LJ, Bjorkman D, Fennerty MB, et al. Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol 2002 Nov;97(11 Suppl):S7-26.
4. Hahn BA, Saunders WB, Maier WC. Differences between individuals with self-reported irritable bowel syndrome (IBS) and IBS-like symptoms. Dig Dis Sci 1997 Dec;42(12):2585-2590.
5. Saito YA, Locke GR, Talley NJ, Zinsmeister AR, Fett SL, Melton LJ, 3rd. A comparison of the Rome and Manning criteria for case identification in epidemiological investigations of irritable bowel syndrome. Am J Gastroenterol 2000 Oct;95(10):2816-2824.
6. Thompson WG, Irvine EJ, Pare P, Ferrazzi S, Rance L. Functional gastrointestinal disorders in Canada: first population-based survey using Rome II criteria with suggestions for improving the questionnaire. Dig Dis Sci 2002 Jan;47(1):225-235.
7. Hungin AP, Whorwell PJ, Tack J, Mearin F. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment Pharmacol Ther 2003 Mar 1;17(5):643-650.
8. Schuster MM. Diagnostic evaluation of the irritable bowel syndrome. Gastroenterol Clin North Am 1991 Jun;20(2):269-278.
9. Farthing MJ. Irritable bowel syndrome: new pharmaceutical approaches to treatment. Baillieres Best Pract Res Clin Gastroenterol 1999 Oct;13(3):461-471.
10. Wald A. Irritable Bowel Syndrome. Curr Treat Options Gastroenterol 1999 Feb;2(1):13-19.
11. Serra J, Azpiroz F, Malagelada JR. Impaired transit and tolerance of intestinal gas in the irritable bowel syndrome. Gut 2001 Jan;48(1):14-19.
12. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006 Apr;130(5):1480-1491.
13. Stewart WF, Liberman JN, Sandler RS, et al. Epidemiology of constipation (EPOC) study in the United States: relation of clinical subtypes to sociodemographic features. Am J Gastroenterol 1999 Dec;94(12):3530-3540.
14. Sonnenberg A, Koch TR. Physician visits in the United States for constipation: 1958 to 1986. Dig Dis Sci 1989 Apr;34(4):606-611.
15. Pare P, Ferrazzi S, Thompson WG, Irvine EJ, Rance L. An epidemiological survey of constipation in canada: definitions, rates, demographics, and predictors of health care seeking. Am J Gastroenterol 2001 Nov;96(11):3130-3137.
16. Heaton KW, Radvan J, Cripps H, Mountford RA, Braddon FE, Hughes AO. Defecation frequency and timing, and stool form in the general population: a prospective study. Gut 1992 Jun;33(6):818-824.
17. Johanson JF, Sonnenberg A, Koch TR. Clinical epidemiology of chronic constipation. J Clin Gastroenterol 1989 Oct;11(5):525-536.
18. Everhart JE, Go VL, Johannes RS, Fitzsimmons SC, Roth HP, White LR. A longitudinal survey of self-reported bowel habits in the United States. Dig Dis Sci 1989 Aug;34(8):1153-1162.
19. Sandler RS, Drossman DA. Bowel habitsinyoung adults not seeking health care. Dig Dis Sci 1987 Aug;32(8):841-845.
20. Koch A, Voderholzer WA, Klauser AG, Muller-Lissner S. Symptoms in chronic constipation. Dis Colon Rectum 1997 Aug;40(8):902-906.
21. American College of Gastroenterology Chronic Constipation Task Force. An evidence-based approach to the management of chronic constipation in North America. Am J Gastroenterol 2005;100 Suppl 1:S1-4.
22. Gershon MD. Serotonin and its implication for the management of irritable bowel syndrome. Rev Gastroenterol Disord 2003;3 Suppl 2:S25-34.
23. Evans BW, Clark WK, Moore DJ, Whorwell PJ. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation. Cochrane Database Syst Rev 2007(4):CD003960.
24. Lembo A, Camilleri M. Chronic constipation. N EnglJ Med 2003 Oct 2;349(14):1360-1368.
25. FDA Announces Discontinued Marketing of GI Drug, Zelnorm, for Safety Reasons FDA; March 30,2007 [cited 2009 May,21]; Available from: http://www.fda.gov/bbs/topics/NEWS/2007/NEW 01597.html.
26. FDA Permits Restricted Use of Zelnorm for Qualifying Patients July 27, 2007 [cited 2009 May 21];Availablefrom: http://www.fda.gov/bbs/topics/NEWS/2007/NEW 01673.html.
27. Tack J, Muller-Lissner S, Bytzer P, et al. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation. Gut 2005 Dec;54(12):1707-1713.
28. Fock KM, Wagner A. Safety, tolerability and satisfaction with tegaserod therapy in Asia-Pacific patients with irritable bowel syndrome with constipation. J Gastroenterol Hepatol 2007 Aug;22(8):1190-1198.
29. Morganroth J, Ruegg PC, Dunger-Baldauf C, Appel-Dingemanse S, Bliesath H, Lefkowitz M. Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects. Am J Gastroenterol 2002 Sep;97(9):2321-2327.
30. Anderson JL, May HT, Bair TL, Muhlestein JB, Horne BD, Carlquist JF. Lack of association of tegaserod with adverse cardiovascular outcomes in a matched case-control study. J Cardiovasc Pharmacol Ther 2009 Sep;14(3):170-175.
31. Johanson JF, Wald A, Tougas G, et al. Effect of tegaserod in chronic constipation: a randomized, double-blind, controlled trial. Clin Gastroenterol Hepatol 2004 Sep;2(9):796-805.
32. Kamm MA, Muller-Lissner S, Talley NJ, et al. Tegaserod for the treatment of chronic constipation: a randomized, double-blind, placebo-controlled multinational study. Am J Gastroenterol 2005 Feb;100(2):362-372.
33. Schoenfeld P. Review article: the safety profile of tegaserod. Aliment Pharmacol Ther 2004 Nov;20 Suppl 7:25-30.
34. Camilleri M. Review article: tegaserod. Aliment Pharmacol Ther 2001 Mar;15(3):277-289.